Coliseo

Head-to-Head Startup Ranking & Discovery

P

Promakhos Therapeutics

Bio · US · Early-stage

promakhos.com ↗

We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.

Ratings are live Elo scores from head-to-head crowd votes — opinion, not fact or financial advice. How it works →